RECURSION PHARMACEUTICALS, INC.
RECURSION PHARMACEUTICALS, INC. (RXRX): 13 pipeline candidates · ~25 mo cash runway · 9 clinical trials. Updated within the last hour.
BioSniper Score
5-factor signal · derived from public data
25.1 months
D/E 0.31 · 0% dilution
Lead: Phase 2/Phase 3
13 candidates
N/A
0 buys · 23 sells (180d)
A transparent, data-derived signal for RECURSION PHARMACEUTICALS, INC.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$1.7B
Cash
$665.2M
Quarterly Burn
$81.1M
Runway
25.1 mo
Revenue
$6.5M
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (13 candidates)
| Drug | Phase |
|---|---|
| EXS73565 | Phase 1 |
| exs74539 | Phase 1 |
| GTAEXS617 | Phase 1/Phase 2 |
| REC-1245 | Phase 1/Phase 2 |
| REC-2282 | Phase 2/Phase 3 |
| REC-3565 | Phase 2 |
| REC-3964 | Phase 2 |
| REC-4209 | Preclinical |
| REC-4539 | Phase 2 |
| REC-4881 | Phase 1/Phase 2 |
Showing 10 of 13 candidates. Sign up for full pipeline.
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
337
Total value held
$1.01B
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 44,488,774 | $136.6M |
| blackrock, inc. | 43,192,306 | $132.6M |
| ark investment management llc | 40,212,769 | $123.5M |
| state street corp | 28,490,638 | $87.5M |
| vanguard portfolio management llc | 22,759,100 | $69.9M |
| softbank group corp. | 13,636,515 | $41.9M |
| geode capital management, llc | 12,275,084 | $37.7M |
| susquehanna international group, llp | 8,385,877 | $25.7M |
| goldman sachs group inc | 6,065,661 | $18.6M |
| data collective iv gp, llc | 5,941,120 | $18.2M |
Showing top 10 of 337 institutional holders of RECURSION PHARMACEUTICALS, INC.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in RECURSION PHARMACEUTICALS, INC.'s pipeline?
RECURSION PHARMACEUTICALS, INC. (RXRX) has 13 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is RECURSION PHARMACEUTICALS, INC.'s lead drug candidate?
RECURSION PHARMACEUTICALS, INC.'s most advanced tracked candidate is EXS73565 (Phase 1) for Relapsed or Refractory B-cell Malignancies.
What is RECURSION PHARMACEUTICALS, INC.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, RECURSION PHARMACEUTICALS, INC. has approximately 25.1 months of cash runway.
What is RECURSION PHARMACEUTICALS, INC.'s market capitalization?
RECURSION PHARMACEUTICALS, INC.'s market capitalization is approximately $1.7B.
Who is the CEO of RECURSION PHARMACEUTICALS, INC.?
Dr. Najat Khan Ph.D. is the chief executive officer of RECURSION PHARMACEUTICALS, INC. (RXRX).
Get the full picture on RECURSION PHARMACEUTICALS, INC.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.